US117097A
(en)
*
|
|
1871-07-18 |
|
Improvement in brick-machines |
US15133A
(en)
*
|
|
1856-06-17 |
|
Machine fob paring |
JPS5144499B1
(es)
|
1970-08-29 |
1976-11-29 |
|
|
JPS5334319B2
(es)
|
1971-12-28 |
1978-09-20 |
|
|
JPS5717624B2
(es)
|
1974-04-17 |
1982-04-12 |
|
|
JPS5484060A
(en)
|
1977-12-12 |
1979-07-04 |
Kyushu Sekisui Kogyo |
Treatment of raw *wakame* by using chlorella extract
|
US4324710A
(en)
|
1980-10-02 |
1982-04-13 |
The Firestone Tire & Rubber Company |
Naturally occurring thermoplastic resins as a substitute for various petroleum-derived materials in rubber stocks
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
JPH0234615Y2
(es)
|
1986-08-08 |
1990-09-18 |
|
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5670373A
(en)
*
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5322678A
(en)
*
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
FR2628833B1
(fr)
|
1988-03-18 |
1993-06-25 |
Pont Sur Sambre Ateliers Mecan |
Dispositif assurant le deconfinement d'une charge militaire contenant un explosif
|
US5126250A
(en)
*
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
IL91778A
(en)
|
1988-09-28 |
1994-10-07 |
Lilly Co Eli |
A method for reducing the heterogeneity of monoclonal antibodies
|
AU634186B2
(en)
|
1988-11-11 |
1993-02-18 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
EP0564531B1
(en)
|
1990-12-03 |
1998-03-25 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1992019759A1
(en)
|
1991-04-25 |
1992-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
US5468634A
(en)
*
|
1991-06-24 |
1995-11-21 |
The University Of North Carolina At Chapel Hill |
Axl oncogene
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
DE69334255D1
(de)
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
BR9204244A
(pt)
|
1992-10-26 |
1994-05-03 |
Cofap |
Ferro fundido cinzento
|
EP0752248B1
(en)
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
EP0671951A4
(en)
|
1992-12-01 |
1997-05-21 |
Protein Design Labs Inc |
HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
WO1996011020A1
(fr)
|
1994-10-07 |
1996-04-18 |
Chugai Seiyaku Kabushiki Kaisha |
Medicament contre la polyarthrite rhumatoide contenant un antagoniste d'interleukine 6 comme principe actif
|
US5888510A
(en)
*
|
1993-07-21 |
1999-03-30 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
DE4419399C1
(de)
|
1994-06-03 |
1995-03-09 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5945311A
(en)
*
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US8017121B2
(en)
*
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
WO1996012503A1
(fr)
*
|
1994-10-21 |
1996-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Remede contre des maladies provoquees par la production d'il-6
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
US5876950A
(en)
|
1995-01-26 |
1999-03-02 |
Bristol-Myers Squibb Company |
Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
|
BR9604884A
(pt)
|
1995-02-28 |
1998-05-19 |
Procter & Gamble |
Preparação de produtos de bebida não carbonatada com estabilidade microbiana superior
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
CN1241944C
(zh)
*
|
1995-09-11 |
2006-02-15 |
协和发酵工业株式会社 |
抗人白介素-5受体α链的抗体
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US20020147326A1
(en)
|
1996-06-14 |
2002-10-10 |
Smithkline Beecham Corporation |
Hexameric fusion proteins and uses therefor
|
SK1499A3
(en)
|
1996-07-19 |
1999-08-06 |
Amgen Inc |
Analogs of cationic proteins
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
JPH10324639A
(ja)
|
1997-03-21 |
1998-12-08 |
Chugai Pharmaceut Co Ltd |
Il−6アンタゴニストを有効成分として含有する感作t細胞関与疾患の予防・治療剤
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20070059302A1
(en)
*
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
AU751659B2
(en)
|
1997-05-02 |
2002-08-22 |
Genentech Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
CA2293829C
(en)
|
1997-06-24 |
2011-06-14 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
CA2296322A1
(en)
|
1997-08-15 |
1999-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
|
US20020187150A1
(en)
*
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
CN1277632A
(zh)
*
|
1997-10-03 |
2000-12-20 |
中外制药株式会社 |
天然人源化抗体
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
EP1074268B1
(en)
|
1998-03-17 |
2008-01-16 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
ES2364266T3
(es)
|
1998-04-03 |
2011-08-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
CA2341029A1
(en)
*
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
DE69942671D1
(de)
*
|
1998-12-01 |
2010-09-23 |
Facet Biotech Corp |
Humanisierte antikoerper gegen gamma-interferon
|
EP1051432B1
(en)
|
1998-12-08 |
2007-01-24 |
Biovation Limited |
Method for reducing immunogenicity of proteins
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6972125B2
(en)
*
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
PT1914244E
(pt)
|
1999-04-09 |
2013-07-26 |
Kyowa Hakko Kirin Co Ltd |
Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
|
DK1188830T3
(da)
|
1999-06-02 |
2010-04-26 |
Chugai Pharmaceutical Co Ltd |
Nyt hæmopoietinreceptorprotein NR10
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
WO2001025454A2
(en)
|
1999-10-04 |
2001-04-12 |
Medicago Inc. |
Method for regulating transcription of foreign genes in the presence of nitrogen
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
CA2393869A1
(en)
|
1999-12-15 |
2001-06-21 |
Genetech,Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
WO2001049698A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
WO2001075454A2
(en)
*
|
2000-04-03 |
2001-10-11 |
Oxford Glycosciences (Uk) Ltd. |
Diagnosis and treatment of alzheimer's disease
|
NZ521540A
(en)
|
2000-04-11 |
2004-09-24 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
AU2001266272B2
(en)
|
2000-05-03 |
2005-09-15 |
Medigene Ag |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
CA2785941C
(en)
|
2000-10-06 |
2017-01-10 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
KR100824824B1
(ko)
|
2000-10-25 |
2008-04-23 |
추가이 세이야쿠 가부시키가이샤 |
아이엘-6 안타고니스트를 유효 성분으로서 함유하는건선의 예방 또는 치료제
|
JP4889187B2
(ja)
*
|
2000-10-27 |
2012-03-07 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
ATE378403T1
(de)
|
2000-11-30 |
2007-11-15 |
Medarex Inc |
Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
IL158376A0
(en)
*
|
2001-04-13 |
2004-05-12 |
Biogen Inc |
Antibodies to vla-1
|
JP4281869B2
(ja)
|
2001-06-22 |
2009-06-17 |
中外製薬株式会社 |
抗グリピカン3抗体を含む細胞増殖抑制剤
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
CN1555411A
(zh)
|
2001-08-03 |
2004-12-15 |
���迨�����\���ɷݹ�˾ |
抗体-依赖性细胞毒性增大的抗体糖基化变体
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
EP1443961B1
(en)
|
2001-10-25 |
2009-05-06 |
Genentech, Inc. |
Glycoprotein compositions
|
US20030190705A1
(en)
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
KR100913714B1
(ko)
|
2001-11-08 |
2009-08-24 |
패시트 바이오테크 코포레이션 |
Igg 항체의 안정한 액상 약학 제형물
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
EP3960855A1
(en)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing proteins
|
EP2338910B1
(en)
*
|
2002-01-18 |
2015-07-08 |
ZymoGenetics, Inc. |
Cytokine receptor Zcytor17 multimers
|
EP1961811B1
(en)
*
|
2002-01-18 |
2010-08-25 |
ZymoGenetics, Inc. |
Cytokine ligand for the treatment of asthma and airway hyper-responsiveness
|
US20030224397A1
(en)
*
|
2002-02-11 |
2003-12-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
WO2003074679A2
(en)
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
US8188231B2
(en)
*
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
JPWO2003085107A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
ゲノムが改変された細胞
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
CA2481925A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for patients having human fc.gamma.riiia
|
JP4628679B2
(ja)
|
2002-04-09 |
2011-02-09 |
協和発酵キリン株式会社 |
Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
US20040018573A1
(en)
|
2002-04-18 |
2004-01-29 |
Power Scott D |
Production of functional antibodies in filamentous fungi
|
JP2004086862A
(ja)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
|
US20050130224A1
(en)
*
|
2002-05-31 |
2005-06-16 |
Celestar Lexico- Sciences, Inc. |
Interaction predicting device
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
US20060141456A1
(en)
*
|
2002-06-12 |
2006-06-29 |
Cynthia Edwards |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
EP1382969A1
(en)
|
2002-07-17 |
2004-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Diagnosis and prevention of cancer cell invasion
|
TW200407335A
(en)
*
|
2002-07-22 |
2004-05-16 |
Chugai Pharmaceutical Co Ltd |
Non-neutralizing antibody to inhibit the inactivation of activated protein C
|
WO2004016740A2
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
AU2003286467B2
(en)
|
2002-10-15 |
2009-10-01 |
Abbvie Biotherapeutics Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB0224082D0
(en)
|
2002-10-16 |
2002-11-27 |
Celltech R&D Ltd |
Biological products
|
EP1572744B1
(en)
|
2002-12-16 |
2010-06-09 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
NZ540730A
(en)
*
|
2002-12-24 |
2010-09-30 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods using same
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
JP2006517109A
(ja)
|
2003-02-07 |
2006-07-20 |
プロテイン デザイン ラブス インコーポレイテッド |
アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
|
US20040223970A1
(en)
*
|
2003-02-28 |
2004-11-11 |
Daniel Afar |
Antibodies against SLC15A2 and uses thereof
|
AU2004229311B2
(en)
|
2003-03-04 |
2009-07-09 |
Alexion Pharmaceuticals, Inc. |
Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
EA009026B1
(ru)
|
2003-03-24 |
2007-10-26 |
Займоджинетикс, Инк. |
Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях
|
JP2004321100A
(ja)
|
2003-04-25 |
2004-11-18 |
Rikogaku Shinkokai |
IgGのFc領域を含むタンパク質の変異体
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP1639009B1
(en)
*
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
PT2272868E
(pt)
|
2003-06-05 |
2015-07-07 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
EP1636264A2
(en)
|
2003-06-24 |
2006-03-22 |
MERCK PATENT GmbH |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
CA2531482A1
(en)
|
2003-06-30 |
2005-01-20 |
Centocor, Inc. |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
JP2005101105A
(ja)
|
2003-09-22 |
2005-04-14 |
Canon Inc |
位置決め装置、露光装置、デバイス製造方法
|
US20060134105A1
(en)
*
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
EP1705251A4
(en)
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
CA2545539A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
BRPI0415505A
(pt)
|
2003-10-17 |
2006-12-12 |
Chugai Pharmaceutical Co Ltd |
agente terapêutico para mesotelioma
|
RS55723B1
(sr)
|
2003-11-05 |
2017-07-31 |
Roche Glycart Ag |
Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
BR122018071968B8
(pt)
|
2003-11-06 |
2021-07-27 |
Seattle Genetics Inc |
conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
US20050142133A1
(en)
*
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
US20050191293A1
(en)
*
|
2003-12-10 |
2005-09-01 |
Shrikant Deshpande |
IP-10 antibodies and their uses
|
NZ547157A
(en)
|
2003-12-10 |
2009-07-31 |
Medarex Inc |
Interferon Alpha Antibodies and their uses
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
AU2004309275B2
(en)
|
2003-12-25 |
2010-12-23 |
Kyowa Kirin Co., Ltd. |
Mutants of anti-CD40 antibody
|
EP1699822B1
(en)
*
|
2003-12-30 |
2008-04-23 |
MERCK PATENT GmbH |
Il-7 fusion proteins with antibody portions, their preparation and their use
|
DK2177537T3
(da)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antistoffer til MAdCAM
|
ATE464908T1
(de)
|
2004-02-11 |
2010-05-15 |
Warner Lambert Co |
Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
|
US8398980B2
(en)
*
|
2004-03-24 |
2013-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Subtypes of humanized antibody against interleuken-6 receptor
|
EP1737890A2
(en)
*
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
KR20070035482A
(ko)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Tag-72에 대한 인간화 항체
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
JP2008504289A
(ja)
|
2004-06-25 |
2008-02-14 |
メディミューン,インコーポレーテッド |
部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加
|
US9012369B2
(en)
|
2004-07-06 |
2015-04-21 |
Pfizer Inc. |
Look-through mutagenesis for developing altered polypeptides with enhanced properties
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
KR20070057839A
(ko)
|
2004-08-19 |
2007-06-07 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
WO2006028936A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
US7572456B2
(en)
|
2004-09-13 |
2009-08-11 |
Macrogenics, Inc. |
Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
US20080233131A1
(en)
|
2004-09-14 |
2008-09-25 |
Richard John Stebbings |
Vaccine
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
US8911726B2
(en)
|
2004-09-22 |
2014-12-16 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human Igg4 antibodies
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
JP5553963B2
(ja)
*
|
2004-10-22 |
2014-07-23 |
アムジエン・インコーポレーテツド |
組換え抗体をリフォールディングする方法
|
AU2005302453A1
(en)
|
2004-10-29 |
2006-05-11 |
Medimmune, Llc |
Methods of preventing and treating RSV infections and related conditions
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
AU2005335714B2
(en)
*
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
CA2586803C
(en)
|
2004-12-14 |
2012-12-11 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
US8728828B2
(en)
|
2004-12-22 |
2014-05-20 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
US20090087478A1
(en)
|
2004-12-27 |
2009-04-02 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
|
EP1831258B2
(en)
|
2004-12-28 |
2023-06-07 |
Innate Pharma S.A. |
Monoclonal antibodies against nkg2a
|
CN101098891B
(zh)
|
2005-01-05 |
2014-05-21 |
F-星生物技术研究与开发有限公司 |
分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
|
CA2595169A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
US20060182743A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Janine Bilsborough |
Methods of treating skin disorders using an IL-31RA antagonist
|
US7700099B2
(en)
*
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
CA2957144C
(en)
*
|
2005-04-08 |
2020-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
SG161281A1
(en)
|
2005-04-15 |
2010-05-27 |
Genentech Inc |
Hgf beta chain variants
|
US8008443B2
(en)
|
2005-04-26 |
2011-08-30 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
US20090028854A1
(en)
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CN101627054A
(zh)
|
2005-07-11 |
2010-01-13 |
马克罗基因公司 |
用人源化抗cd16a抗体治疗自身免疫疾病的方法
|
DK1919503T3
(en)
*
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
CN103450359B
(zh)
|
2005-08-19 |
2018-07-24 |
惠氏有限责任公司 |
抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
|
WO2007032634A1
(en)
|
2005-09-12 |
2007-03-22 |
Industry Foundation Of Chonnam National University |
A method for production of mature natural killer cell
|
JP2009510102A
(ja)
*
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
免疫調節組成物およびその使用
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
JP5191235B2
(ja)
|
2005-10-21 |
2013-05-08 |
中外製薬株式会社 |
心疾患治療剤
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
EP1991581A2
(en)
|
2006-01-10 |
2008-11-19 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
|
WO2007084321A2
(en)
*
|
2006-01-12 |
2007-07-26 |
Alexion Pharmaceuticals, Inc. |
Antibodies to ox-2/cd200 and uses thereof
|
AR059213A1
(es)
|
2006-01-27 |
2008-03-19 |
Univ Keio |
Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
|
KR101413615B1
(ko)
|
2006-03-23 |
2014-07-18 |
바이오악틱 뉴로사이언스 에이비 |
인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
|
KR20090013763A
(ko)
|
2006-03-23 |
2009-02-05 |
기린 파마 가부시끼가이샤 |
인간 트롬보포이에틴 수용체에 대한 아고니스트 항체
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
ES2568436T3
(es)
|
2006-03-31 |
2016-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para controlar la farmacocinética en sangre de anticuerpos
|
CN101495146B
(zh)
|
2006-04-07 |
2012-10-17 |
国立大学法人大阪大学 |
肌肉再生促进剂
|
AU2007249408A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
NZ572565A
(en)
|
2006-05-25 |
2011-04-29 |
Glaxo Group Ltd |
Modified humanised anti-interleukin-18 antibodies
|
RS52643B
(en)
*
|
2006-06-02 |
2013-06-28 |
Regeneron Pharmaceuticals Inc. |
HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
ES2429407T3
(es)
|
2006-06-08 |
2013-11-14 |
Chugai Seiyaku Kabushiki Kaisha |
Agente preventivo o remedio para enfermedades inflamatorias
|
US7858756B2
(en)
*
|
2006-06-15 |
2010-12-28 |
The Board Of Trustees Of The University Of Arkansas |
Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
|
SI2059536T1
(sl)
|
2006-08-14 |
2014-06-30 |
Xencor, Inc. |
Optimirana protitelesa, ki ciljajo CD19
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
MX2009007830A
(es)
|
2007-01-23 |
2009-10-07 |
Univ Shinshu |
Inhibidor de rechazo cronico.
|
JPWO2008090960A1
(ja)
|
2007-01-24 |
2010-05-20 |
協和発酵キリン株式会社 |
ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
DE602008004296D1
(de)
*
|
2007-02-14 |
2011-02-17 |
Vaccinex Inc |
Humanisierte anti-cd100-antikörper
|
HUE042172T2
(hu)
|
2007-02-23 |
2019-06-28 |
Merck Sharp & Dohme |
Genetikailag elõállított anti-il-23P19 antitestek
|
WO2008114733A1
(ja)
|
2007-03-16 |
2008-09-25 |
Kyowa Hakko Kirin Co., Ltd. |
抗Claudin-4抗体
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
GB0708002D0
(en)
|
2007-04-25 |
2007-06-06 |
Univ Sheffield |
Antibodies
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
EP2155790A1
(en)
|
2007-05-31 |
2010-02-24 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
JP6071165B2
(ja)
|
2007-05-31 |
2017-02-01 |
ゲンマブ エー/エス |
安定なIgG4抗体
|
WO2009014263A1
(ja)
|
2007-07-26 |
2009-01-29 |
Osaka University |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
EP2031064A1
(de)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
MX2010002683A
(es)
*
|
2007-09-14 |
2010-03-26 |
Amgen Inc |
Poblaciones de anticuerpos homogeneos.
|
EP3689912A1
(en)
|
2007-09-26 |
2020-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
WO2009041734A1
(ja)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
CN101939425B
(zh)
*
|
2007-09-26 |
2014-05-14 |
中外制药株式会社 |
抗il-6受体抗体
|
SG10201605394SA
(en)
|
2007-09-26 |
2016-08-30 |
Chugai Pharmaceutical Co Ltd |
Modified Antibody Constant Region
|
BRPI0817637A2
(pt)
|
2007-09-28 |
2015-09-08 |
Chugai Pharmaceutical Co Ltd |
anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma
|
CA2701155C
(en)
|
2007-10-02 |
2016-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2203180B1
(en)
|
2007-10-22 |
2012-11-21 |
Merck Serono S.A. |
Single ifn-beta fused to a mutated igg fc fragment
|
CN101918452A
(zh)
*
|
2007-11-15 |
2010-12-15 |
中外制药株式会社 |
与Anexelekto结合的单克隆抗体及其利用
|
RU2531521C2
(ru)
|
2007-12-05 |
2014-10-20 |
Чугаи Сейяку Кабусики Кайся |
Антитело против nr10 и его применение
|
MX2010006097A
(es)
|
2007-12-05 |
2010-08-04 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para tratar el prurito.
|
AU2008338313B2
(en)
|
2007-12-18 |
2014-01-16 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
|
ES2532461T3
(es)
|
2007-12-26 |
2015-03-27 |
Xencor, Inc. |
Variantes de FC con enlazamiento alterado a FCRN
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
JP5608100B2
(ja)
|
2008-02-08 |
2014-10-15 |
メディミューン,エルエルシー |
低下したFcリガンド親和性を有する抗IFNAR1抗体
|
EP4238993A3
(en)
|
2008-04-11 |
2023-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
AU2009246946B2
(en)
|
2008-05-01 |
2013-09-26 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
CN102256623A
(zh)
|
2008-06-05 |
2011-11-23 |
独立行政法人国立癌症研究中心 |
神经浸润抑制剂
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
CN108610416B
(zh)
|
2008-10-13 |
2022-01-14 |
生物医学研究所 |
登革热病毒中和抗体及其用途
|
EP2352521B1
(en)
|
2008-10-14 |
2020-09-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
MX2011005408A
(es)
|
2008-11-25 |
2011-06-16 |
Alder Biopharmaceuticals Inc |
Antagonistas de il-6 para prevenir o tratar la trombosis.
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
WO2010064090A1
(en)
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Process for the modulation of the antagonistic activity of a monoclonal antibody
|
KR20160062207A
(ko)
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
CN102272145B
(zh)
|
2009-01-12 |
2014-07-30 |
通用电气健康护理生物科学股份公司 |
亲和色谱基质
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
KR101456326B1
(ko)
|
2009-04-07 |
2014-11-12 |
로슈 글리카트 아게 |
3가, 이중특이적 항체
|
WO2010131733A1
(ja)
|
2009-05-15 |
2010-11-18 |
中外製薬株式会社 |
抗axl抗体
|
PL2975051T3
(pl)
|
2009-06-26 |
2021-09-20 |
Regeneron Pharmaceuticals, Inc. |
Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
PL2515452T3
(pl)
|
2009-12-18 |
2015-09-30 |
Electronics & Telecommunications Res Inst |
Sposób wysyłania/odbioru danych w systemie bezprzewodowej komunikacji pakietowej, w którym zachodzi jednoczesna komunikacja z pewną liczbą terminali
|
RU2606264C2
(ru)
|
2009-12-25 |
2017-01-10 |
Чугаи Сеияку Кабушики Каиша |
Способ полипептидной модификации для очистки полипептидных мультимеров
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
JP5947727B2
(ja)
|
2010-01-20 |
2016-07-06 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ilt5抗体およびilt5結合抗体断片による免疫調節
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
EP2543727B1
(en)
|
2010-03-02 |
2016-08-31 |
Kyowa Hakko Kirin Co., Ltd. |
Modified antibody composition
|
JP5889181B2
(ja)
*
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN102844332B
(zh)
|
2010-03-11 |
2015-08-19 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
JP5998050B2
(ja)
|
2010-03-31 |
2016-09-28 |
Jsr株式会社 |
アフィニティークロマトグラフィー用充填剤
|
SG184427A1
(en)
|
2010-04-20 |
2012-11-29 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
WO2012020096A1
(en)
|
2010-08-13 |
2012-02-16 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
MX2013005024A
(es)
|
2010-11-08 |
2013-11-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-il-6 receptor administrado subcutaneamente.
|
MY166429A
(en)
|
2010-11-17 |
2018-06-26 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
SG190727A1
(en)
|
2010-11-30 |
2013-07-31 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
BR112013013311A2
(pt)
|
2010-11-30 |
2017-09-19 |
Chugai Pharmaceutical Co Ltd |
agente terapêutico de indução de citotoxicidade
|
PL2651975T3
(pl)
|
2010-12-14 |
2018-04-30 |
Dso Nat Laboratories |
Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
US20140112883A1
(en)
|
2011-04-20 |
2014-04-24 |
Liquidating Trust |
Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
|
JP5729817B2
(ja)
|
2011-06-29 |
2015-06-03 |
日本電信電話株式会社 |
動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、動画像符号化プログラム及び動画像復号プログラム
|
TWI827333B
(zh)
|
2011-09-30 |
2023-12-21 |
日商中外製藥股份有限公司 |
促進抗原消失的抗原結合分子
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
LT2771364T
(lt)
|
2011-10-27 |
2019-09-10 |
Genmab A/S |
Heterodimerinių baltymų gamyba
|
PL2773671T3
(pl)
|
2011-11-04 |
2022-01-24 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
|
WO2013089647A1
(en)
|
2011-12-16 |
2013-06-20 |
Agency For Science, Technology And Research |
Binding molecules against dengue virus and uses thereof
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
US9815909B2
(en)
|
2012-03-13 |
2017-11-14 |
Novimmune S.A. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
EP2832856A4
(en)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
ANTI-LAMP5 ANTIBODIES AND USE THEREOF
|
CN108912215A
(zh)
|
2012-04-02 |
2018-11-30 |
北卡罗来纳-查佩尔山大学 |
用于登革病毒表位的方法和组合物
|
NZ630551A
(en)
|
2012-04-20 |
2017-11-24 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
WO2013173348A1
(en)
|
2012-05-14 |
2013-11-21 |
The Usa, As Represented By The Secretary, Dept. Of Health & Human Services |
Cross-reactive antibodies against dengue virus and uses thereof
|
US20140154270A1
(en)
|
2012-05-21 |
2014-06-05 |
Chen Wang |
Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
|
EP2857419B1
(en)
|
2012-05-30 |
2021-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
JPWO2013180200A1
(ja)
|
2012-05-30 |
2016-01-21 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
AU2013299986B2
(en)
|
2012-08-07 |
2018-05-17 |
Massachusetts Institute Of Technology |
Anti-dengue virus antibodies and uses thereof
|
NZ704771A
(en)
|
2012-08-13 |
2018-02-23 |
Regeneron Pharma |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
EP2894171A4
(en)
|
2012-09-10 |
2016-05-25 |
Kaneka Corp |
ADSORPTION
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
EP2914634B1
(en)
|
2012-11-02 |
2017-12-06 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
EP2970436B1
(en)
|
2013-03-15 |
2018-09-05 |
AbbVie Biotherapeutics Inc. |
Fc variants
|
US20160031985A1
(en)
|
2013-03-15 |
2016-02-04 |
Katherine S. Bowdish |
Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
|
KR102441231B1
(ko)
|
2013-09-27 |
2022-09-06 |
추가이 세이야쿠 가부시키가이샤 |
폴리펩티드 이종 다량체의 제조방법
|
EP3176185A1
(en)
|
2013-11-04 |
2017-06-07 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
AU2015217149B2
(en)
|
2014-02-11 |
2020-09-10 |
Massachusetts Institute Of Technology |
Novel full spectrum anti-dengue antibody
|
CN106211773B
(zh)
|
2014-02-11 |
2021-09-03 |
威特拉公司 |
用于登革病毒的抗体分子及其应用
|
GB201413086D0
(en)
|
2014-07-23 |
2014-09-03 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
JP6630036B2
(ja)
|
2014-09-30 |
2020-01-15 |
Jsr株式会社 |
標的物の精製方法、及び、ミックスモード用担体
|
TWI808330B
(zh)
|
2014-12-19 |
2023-07-11 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
|
TW202248212A
(zh)
|
2015-02-05 |
2022-12-16 |
日商中外製藥股份有限公司 |
包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
|
TW202339800A
(zh)
|
2015-02-27 |
2023-10-16 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
GB201610162D0
(en)
|
2016-06-10 |
2016-07-27 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|